For most companies trading over the counter (OTC), an uplisting to a higher exchange is for the most part, the Holy Grail. Getting there is never easy and for many uplisting is but a fleeting dream. When one looks at the prerequisites for uplisting, it’s not difficult to see why for many this is but a dream.

Companies trading on the lower exchanges have to meet a raft of standards before they can be considered for a listing on exchanges like the NASDAQ or NYSE.

To be listed on the NYSE for instance, a company must have aggregate pre-tax earnings in the prior three years of at least $11 million. In the prior two years, those earnings must be at least $2.2 million and in no year in the prior three years can it have a net loss.

In addition to that, cash reserve requirements are high. A company must have a minimum aggregate cash flow of at least $27.5 million.

Bcmon is a popular Android application which let the Android users to get connected to any Wi-Fi in easy steps. bcmon It takes the Android device to monitor mode and get the requirement works to be done.

Finally, and perhaps most important, companies are required to keep their fiscal performance up to par. Companies can be removed from the exchange if its share price falls below a certain level.

The Rewards of Uplisting Are Well Worth the Effort

Once a company does manage to prove itself and satisfy uplisting requirements, the benefits are tremendous. The biggest benefit is increased visibility. Whereas a lower listing confined a company to simple over the counter exchanges between individuals, a bigger listing gives a company access to the biggest players in the stock market. Institutional investors such as hedge funds now become a part of the conversation for newly uplisted companies.

Newly uplisted companies also benefit from higher trading volumes (greater liquidity). Studies from large exchanges such as the NASDAQ, confirm that post-uplisting, companies can see 3-month average daily volume increase from 59K to 137K – a 132% increase.

In the early periods after uplisting, a company usually gets intense coverage from top analysts, thereby making the company’s stock more attractive to investors. In every way, uplisting is the way to go and we’ve found four companies that are newly minted or submitted their application.

IEGH has submitted its application for uplisting to the NASDAQ and there is a real sense on Wall Street that the company could be newly minted very soon. Driving this underlying sentiment is of course the sheer numbers being done by IEGH in terms of loan growth.

Recently Wall Street got some insight into the pace that IEGH is growing after it announced that its cumulative loan volume has increased by 1,728% from $587,000 to $10,729,023 as of November 30, 2015. IEGH cited three main drivers for the rapid growth in loan volume:

That last driver is worth expanding on, not least because it shows what the company is doing on the ground and ultimately, where it could end up in the online lending space which produced a whopping $12 billion worth of loans in 2014. IEGH prior to July 2015, offered loans in 3 states. That number has been increased to 16 after the company added California, Alabama and Louisiana. The company has stated that it plans to offer loans in 25 states by mid-2016. If that goal is met IEGH will have coverage for 250 million people or roughly 80% of the US population.

It is worth pointing out again that IEGH has already submitted its application for uplisting to the NASDAQ. Investors are therefore well served in keeping a shrewd eye on the company from now on.

Cynapsus Therapeutics Inc. (CYNA) is a specialty pharmaceutical company, engages in developing an enhanced dosing formulation of an approved drug used to treat the symptoms of Parkinson’s disease. The important thing to know too is that CYNA had a recent uplisting to the NASDAQ. The company made good on its plans and had a US re-IPO worth $72.5 million.

Since uplisting CYNA has become one of the most talked about companies on Wall Street and its progress on the ground is gaining wider and wider visibility. Recently CYNA announced that it has successfully completed the CTH-200 bridging study comparing APL-130277 to subcutaneous apomorphine. The CTH-200 study was a single-dose, crossover comparative bioavailability and pharmacokinetic study in healthy volunteers.

The increased liquidity and visibility are strong catalysts for CYAN which incidentally, has traded as high as 18.50 in the last 12 months.

Anavex Life Sciences Corp. (AVXL) is engaged in the discovery and development of drugs for the treatment of Alzheimer’s disease and other conditions of the central nervous system. AVXL also recently got uplisted to the NASDAQ and since then has been on fire. Daily volume levels have soared, so much so that current 30-day average volume now stands at 5.9 million shares. In the last 12 months the stock has hit a high of 14.84.

AVXL has been making good progress with its lead Alzheimer’s drug therapy, ANAVEX 3-71. Late November the company said that ANAVEX 3-71 has tested to be a potent cognitive enhancer in Alzheimer’s disease models and that the pre-clinical results will be published in the scientific journal “Neurodegenerative Disease.”

“At very low doses, it mitigates cognitive deficits and normalizes major pathological hallmarks in Alzheimer’s disease models indicating that ANAVEX 3-71 exerts a comprehensive disease-modifying effect,” said AVXL in the statement.

Company CEO Christopher U. Missling, PhD, recently spoke at the third annual roundtable on the implementation of the Mental Health Parity Addiction and Equity Act (MHPAEA) of 2008. The event which was held on December 8, has served to focus more attention on the growing biotech.

Stellar Biotechnologies, Inc. (SBOT) is a leading player in the sustainable manufacture of Keyhole Limpet Hemocyanin (“KLH”) and on November 3 it announced its uplisting to the NASDAQ.

This is a significant milestone for Stellar and an important step in our corporate growth,” said Frank Oakes, President, Chief Executive Officer and Chairman. “We anticipate that the listing of our shares on NASDAQ will raise our visibility within the investment community and with institutional investors, and will offer our shareholders an opportunity for increased liquidity.”

Since uplisting SBOT has duly seen an increase in both visibility and liquidity. The company is now trading near $9 a share having risen to as much as $12.87 in the last 12 months.

It’s obvious that investors can reap very good upside from companies that are newly uplisted. Companies like IEG Holdings Corp. (OTC: IEGH) therefore offer very good upside opportunity as they crossover into higher valuation and listing standards.

The Silicon Valley Insider is always researching new trade ideas which have the makings for large market moves. Traders are urged to follow our parent outlet, The Wealthy Venture Capitalist on social media (see below) to stay apprised. We are an anti-email media outlet, and as such will only be releasing our reports/ updates/ news through: Text/ SMS, Twitter, Facebook as well as newswire.

This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. The Silicon Valley Insider and its employees are not a Registered Investment Advisors, Broker Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Sometimes human error can attribute to honest mistakes in reporting on issues regarding public companies and overall capital markets, and as such we are not responsible for the complete accuracy in these reports as the reader is required to verify all statements to ensure they are completely accurate. The Silicon Valley Insider encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and Silicon Valley Insider makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects,” “foresee,” “expects,” “will,” “anticipates,” “estimates,” “believes,” “understands,” or that by statements indicating certain actions “may,” “could,” or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day closing price and the high of day price during our promotional coverage.

The Silicon Valley Insider’s parent company has been and will be compensated $5,000 per month by IEG Holdings.

Readers must visit our website at www.wealthyventurecapitalist.com in order to view our entire disclaimer which covers most of the risks, biases and liability releases to have a full understanding after reading this article.

Search

Twitter

About Us

The Wealthy venture capitalist is a series of industry-focused Investment articles focused on showing everyday Investors new opportunities in rapidly growing, little-known stocks in 4 of the markets hottest sectors: Biotech, Technology, Medical and Recreational Marijuana, and Consumer products.

About Us

The Wealthy Venture capitalist is a series of industry-focused Investment articles focused on showing everyday Investors new opportunities in rapidly growing, little-known stocks in 4 of the markets hottest sectors: Biotech, Technology, Medical and Recreational Marijuana, and Consumer products.

Distribution Policy

Comprehensive Report Distribution – Syndicated news stories are routed to many major outlets

Report Publication Announcements (press releases) – Report publication announcements are systematically made to the global financial community via press releases, which further lead to news coverage through additional, global journalistic channels.

Global Research Visibility – Powered by WVC’s strategic partnerships with companies around the world, our news stories receive unprecedented domestic and international exposure.